Status:
UNKNOWN
Effect of Momordica Charantia Administration on Anthropometric Indicators in Patients With Obesity
Lead Sponsor:
University of Guadalajara
Conditions:
Obesity
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
Momordica charantia has shown to exert anti-obesity effects through numerous mechanisms of action described in preclinical studies. Important reductions in body weight and other anthropometric indicat...
Detailed Description
A randomized, double-blind, placebo controlled clinical trial is carried out in 24 patients with obesity according to the body mass index. Patients are assigned to two different arms: one group recei...
Eligibility Criteria
Inclusion
- Diagnosis of obesity type I according to body mass index (IMC: 30.0 - 34.9 kg/m2)
- Body weight without variations above or under 5% in the last three months before entering the study
- Fasting plasma glucose: \<126 mg/dL
- Total cholesterol: \<240 mg/dL
- Triglycerides: \<400 mg/dL
- Women in childbearing years must have a contraceptive method
- Letter of consent and release signed by each patient
Exclusion
- Women with confirmed or suspected pregnancy
- Women under lactation and/or puerperium
- Known uncontrolled renal, hepatic, cardiovascular or thyroid disease
- Physical impossibility for taking pills
- Known hypersensibility to the Momordica charantia or placebo
Key Trial Info
Start Date :
January 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04916379
Start Date
January 21 2020
End Date
September 1 2021
Last Update
August 31 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara
Guadalajara, Jalisco, Mexico, 44340